Israel Englander Enanta Pharmaceuticals Inc Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Millennium Management LLC holds 731,295 shares of ENTA stock, worth $6.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

731,295

Previous 683,143 7.05%

Holding current value

$6.83 Million

Previous $8.86 Million 14.41%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$10.05 - $16.54 $483,927 - $796,434	48,152 Added 7.05%	731,295 $7.58 Million
Q2 2024 Aug 14, 2024	SELL	$11.43 - $17.02 $264,090 - $393,247	-23,105 Reduced 3.27%	683,143 $8.86 Million
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $593,641 - $1.03 Million	-58,893 Reduced 7.7%	706,248 $12.3 Million
Q4 2023 Feb 14, 2024	BUY	$8.18 - $10.78 $4.35 Million - $5.73 Million	531,654 Added 227.7%	765,141 $7.2 Million
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $1.92 Million - $3.69 Million	92,704 Added 65.85%	233,487 $5 Million
Q1 2023 May 15, 2023	BUY	$38.82 - $54.59 $3.29 Million - $4.62 Million	84,700 Added 151.03%	140,783 $5.69 Million
Q4 2022 Feb 14, 2023	BUY	$40.77 - $53.73 $754,204 - $993,951	18,499 Added 49.22%	56,083 $2.61 Million
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $707,351 - $1.04 Million	14,648 Added 63.86%	37,584 $1.95 Million
Q2 2022 Aug 15, 2022	SELL	$38.13 - $76.93 $1.63 Million - $3.29 Million	-42,797 Reduced 65.11%	22,936 $1.08 Million
Q1 2022 May 16, 2022	BUY	$56.06 - $74.11 $2.8 Million - $3.7 Million	49,901 Added 315.19%	65,733 $4.68 Million
Q4 2021 Feb 14, 2022	BUY	$60.19 - $97.37 $19,922 - $32,229	331 Added 2.14%	15,832 $1.18 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $5.14 Million - $7.35 Million	-125,241 Reduced 88.99%	15,501 $881,000
Q2 2021 Aug 16, 2021	BUY	$43.76 - $53.11 $5.12 Million - $6.21 Million	116,897 Added 490.24%	140,742 $6.19 Million
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $6.38 Million - $8.4 Million	-152,924 Reduced 86.51%	23,845 $1.18 Million
Q4 2020 Feb 16, 2021	BUY	$41.16 - $47.47 $2.09 Million - $2.41 Million	50,856 Added 40.39%	176,769 $7.44 Million
Q3 2020 Nov 16, 2020	BUY	$43.36 - $53.53 $3.86 Million - $4.77 Million	89,026 Added 241.35%	125,913 $5.76 Million
Q2 2020 Aug 14, 2020	SELL	$46.37 - $57.58 $2.01 Million - $2.49 Million	-43,296 Reduced 54.0%	36,887 $1.85 Million
Q1 2020 May 14, 2020	BUY	$40.22 - $62.0 $1.72 Million - $2.65 Million	42,751 Added 114.21%	80,183 $4.12 Million
Q4 2019 Feb 14, 2020	BUY	$57.95 - $66.61 $1.84 Million - $2.12 Million	31,811 Added 565.93%	37,432 $2.31 Million
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $3.59 Million - $5.27 Million	-59,731 Reduced 91.4%	5,621 $337,000
Q2 2019 Aug 15, 2019	SELL	$81.3 - $97.35 $52.4 Million - $62.7 Million	-644,192 Reduced 90.79%	65,352 $5.51 Million
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $45 Million - $53.9 Million	553,574 Added 354.92%	709,544 $13.8 Million
Q1 2019 May 14, 2019	BUY	$69.08 - $105.66 $9.35 Million - $14.3 Million	135,325 Added 655.49%	155,970 $14.9 Million
Q4 2018 Feb 14, 2019	BUY	$65.41 - $84.65 $1.35 Million - $1.75 Million	20,645 New	20,645 $1.46 Million
Q3 2018 Nov 14, 2018	SELL	$85.46 - $126.37 $362,863 - $536,567	-4,246 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$81.85 - $120.51 $7.04 Million - $10.4 Million	-86,070 Reduced 95.3%	4,246 $492,000
Q1 2018 May 15, 2018	SELL	$57.91 - $92.15 $7.56 Million - $12 Million	-130,529 Reduced 59.1%	90,316 $7.31 Million
Q4 2017 Feb 14, 2018	BUY	$45.65 - $59.37 $10.1 Million - $13.1 Million	220,845	220,845 $13 Million

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account